Myocardial protection is compromised in patients with a patent internal mammary artery (IMA) graft. We assessed the advantages of systemic hyperkalemia with mild hypothermia for valve surgery in patients with a patent IMA graft. Nine patients (mean age 71.5"7.0 years) with a patent IMA graft underwent valve surgery from May 2004 to July 2009. Of those, eight underwent aortic valve replacement and one mitral repair, with two double-valve surgery. Antegrade and retrograde blood cardioplegia were performed intermittently, and systemic potassium was given to all. The lowest bladder temperature was 27.2"2.4 8C, and the initial and peak systemic potassium levels were 6.8"1.4 and 8.0"1.6 mEqyl, respectively, while potassium at the end of the cardiopulmonary bypass procedure after sufficient modified ultrafiltration was reduced to 5.5"0.6 mEqyl. There was one hospital death due to ischemic colitis. Cardiac arrest was easily achieved in each patient without IMA or aortocoronary graft injury. The postoperative peak creatine kinase-MB level was 33"17 IUyl, with no ST changes seen in electrocardiogram findings or new asynergy seen in echocardiogram findings. Systemic hyperkalemia and mild hypothermia for valve surgery in patients with a patent IMA graft is a good option to reduce graft and myocardial injuries.
Introduction
The risks of valve surgery in patients with a patent internal mammary artery (IMA) are not inconsiderable w1x, with the rate of mortality in large-scale reports reported to range from 12 to 17% for aortic valve replacement (AVR) following a previous coronary artery bypass graft (CABG) w2, 3x. Protection of the IMA graft is crucial for uneventful surgery. Therefore, surgical options have been suggested, including (1) deep hypothermia with or without circulatory arrest, (2) a beating-heart procedure with continuous retrograde or antegrade coronary perfusion, (3) endovascular control of the IMA graft, and (4) supraclavicular control of the IMA graft. In addition, Tabata et al. reported that minimal access aortic valve surgery contributed to suppress operative mortality in patients who underwent a reoperation, including those with a patent IMA graft w4x. In the present study, we examined myocardial and IMA protection provided by an IMA non-touch technique performed using mild hypothermia and systemic hyperkalemia in patients with a patent IMA graft.
Methods

Patients and procedures
Between May 2004 and July 2009, nine patients (mean age 71.5"7.0 years) with a patent IMA graft underwent *Corresponding author. Tel.: q81 6 6833 5012; fax: q81 6 6872 7486. E-mail address: tomofujita@nifty.com (T. Fujita).
valve surgery. The interval from previous operations was 7.7"5.8 years. Five patients were classified as New York Heart Association (NYHA) III or IV, and the EuroSCORE predicted mortality rate was 27.8"22.1%. The distribution of patent grafts is shown in the Table 1. The anatomical positions of the grafts in each patient were evaluated by three-dimensional computed assisted tomographic scanning in addition to coronary angiography. Nine IMA grafts, three sequential Y-composite grafts, and one single Y-composite graft were patent w5x. Six patients underwent AVR, one mitral repair, and two aortic and mitral valve surgery, with CABG performed concomitantly in three. All patients underwent valve surgery with a redo full sternotomy and regular cross-clamping technique. No IMA dissection was attempted in any.
Myocardial protection and cardiopulmonary bypass
Following placement of an aortic cross-clamp (AXC), antegrade and retrograde tepid blood cardioplegia were given intermittently every 20-30 min, as well as terminal retrograde cardioplegia at the end of the AXC period. The crystalloid which contained 20 mEq of potassium chloride, 5 ml of acid citrate dextrose formula A (ACD-A) solution and 0.75 mg of dirtiazem in 500 ml of lactate ringer solution was mixed with blood by the ratio of 1:2 for initial cardioplegia and 1:4 for maintenance cardioplegia. Twenty mlykg of initial cardioplegia and 10-20 mlykg of maintenance cardioplegia were given in pressure control manner as 70 mmHg for antegrade fashion and 30 mmHg for retDownloaded from https://academic.oup.com/icvts/article-abstract/11/1/3/724205 by guest on 25 January 2019 LIMA, left internal mammary artery; LAD, left anterior descending artery; RIMA, right internal mammary artery; RA, radial artery; PL, posterolateral branch; rtPL, right posterolateral branch; Dx, diagonal branch; SVG, saphenous vein graft; PDA, posterior descending artery; RCA, right coronary artery conduit. Fig. 1 . Changes in serum potassium levels are shown. The basal potassium level (On CPB) was 3.9"0.6 mEqyl, which then elevated to 6.8"1.4 mEqyl after giving cardioplegia and potassium injection (Clamp). The peak potassium level (Peak) was 8.0"1.3 mEqyl, which decreased to 7.0"1.2 mEqyl after modified ultrafiltration at the time of releasing the aortic cross-clamp (Declamp) and further to 5.5"0.6 mEqyl at the end of CPB (Off CPB). CPB, cardiopulmonary bypass.
rograde fashion. A selective antegrade cardioplegic cannula was inserted into both coronary ostia to block backflow from the coronary artery. Potassium was given systemically until the level in serum had increased to more than 6 mEqyl, with additional potassium given when cardiac activity was observed. Continuous ultrafiltration was commenced during the AXC period to decrease the potassium level. During cardiopulmonary bypass (CPB), blood was drained from venous line and returned to venous reservoir using roller pump and hemofilter (Terumo CXHC11S, Terumo Corp., Tokyo, Japan, or Jostra BC 140 plus, Jostra Corp., Hirrlingen, Germany) was interposed without suction applied. When potassium levels were high at the end of CPB, the inlet of tubing was switched to root cannula and the outlet was switched to arterial line to continue ultrafiltration. Mild hypothermia was introduced and the lowest bladder temperature in the patients reached 27.2"2.4 8C.
Results
There was one hospital death due to global ischemic colitis which was supposed to occur because of postoperative restricted perfusion caused by low cardiac output and severe diffuse arteriosclerosis. His EuroSCORE predicted mortality rate was 82.5%. This high score was calculated because of double valve surgery for the 75 year old male patient with chronic obstructive pulmonary disease, carotid artery occlusion, chronic renal dysfunction with 220 mmolyl creatinine level, low ejection fraction -20% and pulmonary hypertension with 67 mmHg systolic pressure. No other major postoperative complications were observed and the remaining eight patients were discharged after an ICU stay of 6.9"3.1 days and hospital stay of 33"17 days.
Cardiac arrest was easily achieved in each patient without IMA or aortocoronary graft injury. The CPB and AXC times were 216"75 and 126"41 min, respectively. The total amount of injected potassium except for cardioplegia was 78"46 mEq and total amount subjected to ultrafiltration was 14.2"5.9 l. The initial and peak potassium levels were 6.8"1.4 and 8.0"1.6 mEqyl, respectively, while it was reduced to 5.5"0.6 mEqyl at the end of CPB (Fig. 1) . The postoperative peak creatine kinase-MB level was 33"17 IUyl, with no ST changes in electrocardiogram findings and no new asynergy in echocardiogram findings seen postoperatively.
Discussion
The present IMA non-touch technique was satisfactory for valve surgery for patients with a patent ITA graft, and without myocardial or IMA damage, though one died due to ischemic colitis. The method is simple to perform and can achieve cardiac arrest without clamping the patent IMA. Our experience indicates that milder hypothermia at 32 8C and a lower systemic potassium level of 6-7 mEqyl are enough to maintain cardiac arrest. Although extracellular potassium is anticipated to reduce vascular tone by affecting potassium channels or Na yK -ATPase, we have notexperienced adverse events, such as hypotension by administration of potassium w6x. In addition, commencing modified ultrafiltration before releasing the AXC is recommended, as time is required for the potassium level to decrease. Our current strategy is composed of the following: (1) IMA non-touch, (2) intermittent antegrade and retrograde tepid blood cardioplegia with terminal cardioplegia at the end, (3) potassium at 20-40 mEq given systemically at first, then added according to cardiac activity and potassium level, (4) a target potassium level of 7.0 mEqyl, (5) commencement of modified ultrafiltration in the middle of the AXC period, and (6) mild hypothermia of 32 8C. Moderate hypothermia without systemic hyperkalemia may be enough to achieve fibrillative arrest and to carry out the procedure in safe, as Byrne et al. stated w7, 8x . Furthermore, systemic hyperkalemia can prolong the bypass time for patients with an altered renal function, although ultrafiltration is effective to remove potassium. However, the combination of mild hyperkalemia and mild hypothermia may provide an alternative less invasive strategy.
